Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Panc ASCO

<< Previous

Bullboard Posts

Next >>

Comment by Buckhenryon Jan 27, 2024 3:56pm

422 Views

Post# 35848759

RE:Panc ASCO

Has anyone noticed how many advertisements there are on TV for diabetes targeting obese folks. This is a mega huge market for the drug companies. Where do you think they spend their R&D money for greatest ROI?? Don't get me wrong here I think cancer and heart disease and alzheimers are terrible diseases and it is admirable for the biotechs to come up with drugs but when you look at ROI the diabetes and obesity drugs make them lots of money.

<< Previous

Bullboard Posts

Next >>

Who, why, and what of the great "Crypto Surge"